Sign In
Buy ALX
$281.63
-2.52 (-0.89%)
At Close: Jul 17, 2026
New Strong Buy Stocks for May 29th
07:06am, Thursday, 29'th May 2025
ALX, SPFI, BWB, NIC and WTKWY have been added to the Zacks Rank #1 (Strong Buy) List on May 29, 2025.
Are Finance Stocks Lagging Alexander's (ALX) This Year?
10:45am, Tuesday, 27'th May 2025
Here is how Alexander's (ALX) and Berkeley Group Holdings PLC Unsponsored ADR (BKGFY) have performed compared to their sector so far this year.
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ther
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
08:00am, Tuesday, 13'th May 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline
All You Need to Know About Alexander's (ALX) Rating Upgrade to Strong Buy
01:05pm, Thursday, 08'th May 2025
Alexander's (ALX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:30am, Thursday, 08'th May 2025
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase
Alexander's (ALX) Q1 FFO Beat Estimates
11:05am, Monday, 05'th May 2025
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.57 per share. This compares to FFO of $4.98 per share a year ago.
Alexander's Announces First Quarter Financial Results
08:58am, Monday, 05'th May 2025
PARAMUS, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended March 31, 2025 today and reported:
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
08:00am, Friday, 02'nd May 2025
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a p
Sell These 10 REITs While You Still Can
06:34am, Thursday, 01'st May 2025
This neither the best of times nor the worst of times for REIT investors. This article presents a list of 10 REITs that would merit a Sell rating even in the best of times, given their current conditi
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
11:39am, Wednesday, 30'th Apr 2025
PARAMUS, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and dem
SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipelin
Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
12:13pm, Thursday, 24'th Apr 2025
PARAMUS, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10Q for the quarter ended March 31, 2025 with the U.S. S
New Strong Buy Stocks for April 10th
08:20am, Thursday, 10'th Apr 2025
ALX, TAP, TEF, SFM and CBNA have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2025.
